Table 1.
The Association of HNRNPM Expression With Clinical Characteristics in 240 Patients With HCC
| Characteristics | HNRNPM |
P-value | |
|---|---|---|---|
| Low | High | ||
| Number of patients | 120 | 120 | |
| Age, y | 54.6 ± 10.8 | 51.6 ± 11.4 | .030 |
| Sex | .406 | ||
| Female | 15 (12.5) | 11 (9.2) | |
| Male | 105 (87.5) | 109 (90.8) | |
| HBV | .432 | ||
| Negative | 15 (13.6) | 11 (10.2) | |
| Positive | 95 (86.4) | 97 (89.8) | |
| Anti-HCV | .566 | ||
| Negative | 114 (98.3) | 114 (99.1) | |
| Positive | 2 (1.7) | 1 (0.9) | |
| Postoperative TACE | 1.000 | ||
| No | 71 (59.2) | 71 (59.2) | |
| Yes | 49 (40.8) | 49 (40.8) | |
| Postoperative antivirus | .801 | ||
| No | 112 (93.3) | 111 (92.5) | |
| Yes | 8 (6.7) | 9 (7.5) | |
| Ascites | .582 | ||
| No | 112 (93.3) | 114 (95.0) | |
| Yes | 8 (6.7) | 6 (5.0) | |
| Macrovascular invasion | .811 | ||
| No | 111 (92.5) | 110 (91.7) | |
| Yes | 9 (7.5) | 10 (8.3) | |
| Microvascular invasion | .025 | ||
| No | 20 (36.4) | 6 (15.4) | |
| Yes | 35 (63.6) | 33 (84.6) | |
| Lymph node involved | 1.000 | ||
| No | 118 (98.3) | 118 (98.3) | |
| Yes | 2 (1.7) | 2 (1.7) | |
| Tumor number | < .001 | ||
| Single | 113 (94.2) | 76 (63.3) | |
| Multiple | 7 (5.8) | 44 (36.7) | |
| Tumor grade | < .001 | ||
| I/II | 92 (78.0) | 53 (44.9) | |
| III/IV | 26 (22.0) | 65 (55.1) | |
| Tumor diameter, cm | < .001 | ||
| <5 | 86 (71.7) | 56 (46.7) | |
| ≥5 | 34 (28.3) | 64 (53.3) | |
| Preoperative ALT, U/L | .206 | ||
| <45 | 69 (67.6) | 72 (75.8) | |
| ≥45 | 33 (32.4) | 23 (24.2) | |
| Preoperative AST, U/L | .591 | ||
| <45 | 75 (73.5) | 73 (76.8) | |
| ≥45 | 27 (26.5) | 22 (23.2) | |
| Preoperative bilirubin, um/L | .283 | ||
| <28 | 99 (99.0) | 91 (96.8) | |
| ≥28 | 1 (1.0) | 3 (3.2) | |
| Preoperative AFP, ng/mL | .007 | ||
| <400 | 84 (73.7) | 53 (55.8) | |
| ≥400 | 30 (26.3%) | 42 (44.2%) | |
Note: Data are presented as number (%) or mean ± standard deviation.
Note: Boldface P values indicate statistical significance.
AFP, α-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HNRNPM, heterogeneous nuclear ribonucleoprotein M; TACE, transhepatic arterial chemotherapy and embolization.